Orexigen (OREX) Gains On Potential Marketing Approval for Mysimba in Europe

Shares of Orexigen Therapeutics, Inc. (OREX) are higher by 4.77% to $7.25 in mid-morning trading on Thursday, as the stock continues to see gains following a potential marketing authorization for Mysimba in Europe. During today’s trading session, OREX opened 3 cents lower from the previous close but it has managed to move up to currently […] View the full post at: Orexigen (OREX) Gains On Potential Marketing Approval for Mysimba in Europe Related posts: American Southern Bank Goes Bust Amazon Acquires Zappos.com for $807 mln
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.